Congressional Democrats are already laying the groundwork for major healthcare investigations if they win back Congress in November. From drug pricing and private equity to AI and federal contracting, healthcare companies could face intense public scrutiny — and experts say the time to prepare is now, not after Election Day.
With the 2026 midterms on the horizon, congressional Democrats are quietly building investigative frameworks targeting the healthcare industry — and they're not waiting for election results to get started. Staff members are already requesting that companies preserve records and cultivating outside sources, meaning firms that delay their response could find themselves scrambling under tight timelines and intense public pressure.
The scope of potential investigations is broad. Key focus areas include drug pricing and insurance costs, private equity ownership of hospitals and nursing homes, hospital consolidation, and the use of AI in prior authorization decisions. If Democrats regain the majority, oversight tied to the Trump administration — including conflicts of interest, regulatory decisions, and federal contracting — is also expected to ramp up significantly.
Key Takeaways:
Why it matters: Congressional investigations play out in public, bringing simultaneous legal, reputational, and media risks. Regardless of which party controls Congress after November, the healthcare industry should expect sustained scrutiny — and the window to get ahead of it is closing fast.
